Indaptus Therapeutics, Inc. (INDP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Indaptus Therapeutics, Inc. (INDP) trades at $2.71 with AI Score 26/100 (Grade F). Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focused on developing anti-cancer and anti-viral immunotherapies. Market cap: $4.74M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for INDP: INDP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INDP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INDP: 1/1 perspectives are bearish.
How is this calculated? →Indaptus Therapeutics, Inc. (INDP) Healthcare & Pipeline Overview
Indaptus Therapeutics, Inc. is a pre-clinical stage biotechnology firm specializing in anti-cancer and anti-viral immunotherapies, with Decoy20 as its lead candidate targeting a range of tumors and viral infections. The company operates within the competitive biotechnology sector, focusing on innovative approaches to unmet medical needs.
What Is the Investment Thesis for INDP?
Indaptus Therapeutics presents a high-risk, high-reward investment opportunity typical of pre-clinical biotechnology firms. The primary value driver is the successful development and commercialization of Decoy20. Positive Phase I clinical trial results for Decoy20 in lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as HBV and HIV, could serve as a significant catalyst, potentially leading to partnerships or further funding. The company's small size and limited resources present risks, as does the inherent uncertainty of drug development. The company's P/E ratio is currently -0.12, reflecting its pre-revenue status. Investors should closely monitor clinical trial progress and funding runway.
Based on FMP financials and quantitative analysis
INDP Key Highlights
- Lead candidate Decoy20 is in Phase I clinical trials targeting multiple cancers and viral infections.
- The company rebranded from Intec Parent, Inc. to Indaptus Therapeutics, Inc. in August 2021, signaling a strategic shift.
- Indaptus Therapeutics operates with a lean team of 7 employees, maximizing resource allocation to R&D.
- The company's headquarters are located in New York City, providing access to a strong network of healthcare and biotech resources.
- The company's P/E ratio is currently -0.12, reflecting its pre-revenue status.
Who Are INDP's Competitors?
INDP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GTBP GT Biopharma, Inc. | $0.49 | +4.92% | $5.26M | — |
| NKGN NKGen Biotech, Inc. Common Stock | $0.06 | +0.00% | $7.84M | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INDP's Key Strengths?
- Novel immunotherapy approach targeting multiple cancers and viral infections.
- Lead candidate Decoy20 in Phase I clinical trials.
- Lean and focused team maximizing resource allocation.
- Strong intellectual property protection.
What Are INDP's Weaknesses?
- Pre-clinical stage company with limited financial resources.
- High dependence on the success of Decoy20.
- Small team size may limit operational capacity.
- Lack of established commercial infrastructure.
What Could Drive INDP Stock Higher?
- Phase I clinical trial results for Decoy20 in lymphoma, hepatocellular, colorectal, and pancreatic tumors.
- Announcement of strategic partnerships with pharmaceutical companies.
- Progress in securing additional funding for research and development.
- Expansion of Decoy20 clinical trials to additional indications.
What Are the Key Risks for INDP?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Decoy20.
- Competition from larger pharmaceutical companies with more resources.
- Regulatory delays or rejection of Decoy20.
- Difficulty securing funding to support research and development.
- Dependence on a small team and limited resources.
What Are the Growth Opportunities for INDP?
- Expansion of Decoy20 Clinical Trials: Indaptus Therapeutics has the opportunity to expand the clinical trials for Decoy20 to include additional cancer types and viral infections. This expansion could broaden the potential market for Decoy20 and increase its value. The global market for cancer therapies is projected to reach $286 billion by 2028, offering a substantial opportunity for successful candidates. Timeline: Ongoing, contingent on Phase I results and funding.
- Strategic Partnerships: Indaptus Therapeutics can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of Decoy20. These partnerships could provide access to funding, expertise, and distribution networks. The pharmaceutical industry is actively seeking innovative therapies to bolster their pipelines, making strategic partnerships a viable growth strategy. Timeline: Within the next 2-3 years.
- Development of New Immunotherapy Products: Indaptus Therapeutics can leverage its expertise in immunotherapy to develop new products targeting other cancers and viral infections. This diversification could reduce the company's reliance on Decoy20 and create new revenue streams. The market for immunotherapy products is expected to continue growing rapidly, driven by advances in research and technology. Timeline: Long-term, dependent on research and development efforts.
- Out-licensing of Technology: Indaptus Therapeutics could out-license its technology to other companies for specific applications or geographic regions. This strategy could generate revenue without requiring the company to invest in manufacturing and commercialization infrastructure. The out-licensing market is active, with many companies seeking access to innovative technologies. Timeline: Ongoing, opportunistic.
- Acquisition by a Larger Pharmaceutical Company: Indaptus Therapeutics could be acquired by a larger pharmaceutical company seeking to expand its oncology or infectious disease portfolio. An acquisition would provide shareholders with a return on their investment and validate the company's technology. The pharmaceutical industry is consolidating, with larger companies acquiring smaller biotech firms to gain access to new therapies. Timeline: Potential exit strategy, dependent on clinical trial results and market conditions.
What Opportunities Does INDP Have?
- Expansion of Decoy20 clinical trials to additional indications.
- Strategic partnerships with larger pharmaceutical companies.
- Development of new immunotherapy products.
- Out-licensing of technology.
What Threats Does INDP Face?
- Clinical trial failures.
- Competition from larger pharmaceutical companies.
- Regulatory hurdles.
- Difficulty securing funding.
What Are INDP's Competitive Advantages?
- Proprietary immunotherapy technology targeting specific cancer and viral pathways.
- Early-stage clinical trial data demonstrating potential efficacy of Decoy20.
- Experienced management team with expertise in drug development and commercialization.
- Intellectual property protection through patents and trade secrets.
What Does INDP Do?
Indaptus Therapeutics, Inc., established in 2021 and headquartered in New York City, is a pre-clinical biotechnology company dedicated to the development of innovative immunotherapy products targeting cancer and viral infections. Formerly known as Intec Parent, Inc., the company rebranded to Indaptus Therapeutics, Inc. in August 2021, marking a strategic shift towards its current focus. The company's lead clinical oncology candidate, Decoy20, is currently in Phase I clinical trials. Decoy20 is being investigated for its potential to demonstrate single-agent activity and/or combination therapy-based durable responses in various cancers, including lymphoma, hepatocellular carcinoma, colorectal cancer, and pancreatic tumors. Additionally, Decoy20 is being explored for its efficacy against hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection. Indaptus Therapeutics is committed to advancing its pipeline of immunotherapy products to address significant unmet medical needs in oncology and infectious diseases. The company operates with a lean team of 7 employees, focusing its resources on research and development efforts to bring novel therapies to market.
What Products and Services Does INDP Offer?
- Develops anti-cancer immunotherapy products.
- Develops anti-viral immunotherapy products.
- Focuses on single agent activity and combination therapy.
- Conducts Phase I clinical trials for Decoy20.
- Targets lymphoma, hepatocellular, colorectal, and pancreatic tumors.
- Targets hepatitis B virus (HBV) infection.
- Targets human immunodeficiency virus (HIV) infection.
How Does INDP Make Money?
- Develops and patents novel immunotherapy technologies.
- Conducts pre-clinical and clinical trials to evaluate the safety and efficacy of its products.
- Seeks partnerships with larger pharmaceutical companies for late-stage development and commercialization.
- Potentially out-licenses its technology to generate revenue.
What Industry Does INDP Operate In?
The biotechnology industry is characterized by intense competition, high R&D costs, and a lengthy regulatory approval process. Companies like Indaptus Therapeutics operate in a landscape dominated by larger pharmaceutical firms and specialized biotech companies. The market for cancer immunotherapy is experiencing rapid growth, driven by advances in understanding the immune system's role in fighting cancer. The success of companies like Indaptus depends on their ability to develop novel therapies that demonstrate clinical efficacy and safety. The company's focus on both cancer and viral infections diversifies its potential market opportunities.
Who Are INDP's Key Customers?
- Patients with lymphoma, hepatocellular carcinoma, colorectal cancer, and pancreatic tumors.
- Patients with hepatitis B virus (HBV) infection.
- Patients with human immunodeficiency virus (HIV) infection.
- Pharmaceutical companies seeking to license or acquire novel immunotherapy technologies.
FY2026 estForward Outlook
Wall Street analysts project Indaptus Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-6.34.
F-Score 3/9Financial Health
Indaptus Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
INDP Valuation & Market Position
With a $4.74M market cap, Indaptus Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, INDP's quantitative score of 26/100 is below the peer average of 72/100.
INDP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel immunotherapy approach targeting multiple cancers and viral infections.
- Lead candidate Decoy20 in Phase I clinical trials.
- Lean and focused team maximizing resource allocation.
- Strong intellectual property protection.
Bear Case
- Pre-clinical stage company with limited financial resources.
- High dependence on the success of Decoy20.
- Small team size may limit operational capacity.
- Lack of established commercial infrastructure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
INDP Latest News
-
Ouster, Datavault AI, Paranovus Entertainment Technology And Other Big Stocks Moving Higher On Monday
benzinga · Jun 15, 2026
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Jun 11, 2026
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Jun 10, 2026
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Jun 8, 2026
INDP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INDP.
Price Targets
Wall Street price target analysis for INDP.
INDP MoonshotScore
What does this score mean?
The MoonshotScore rates INDP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Ouster, Datavault AI, Paranovus Entertainment Technology And Other Big Stocks Moving Higher On Monday
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Monday's After-Market Session
Leadership: David Elliot Lazar
Managing Director
David Elliot Lazar serves as the Managing Director of Indaptus Therapeutics, Inc. With a background in finance and management, Lazar has experience in guiding early-stage companies through critical phases of development. His expertise includes capital raising, strategic planning, and operational management. Prior to joining Indaptus, Lazar held various leadership positions in the financial sector, focusing on investment and corporate finance. He brings a strong understanding of the biotechnology industry and the challenges faced by emerging companies in this space.
Track Record: Since joining Indaptus Therapeutics, David Elliot Lazar has focused on advancing the development of Decoy20 and securing funding for clinical trials. He has overseen the company's rebranding and strategic shift towards immunotherapy. His leadership has been instrumental in navigating the complex regulatory landscape and building relationships with key stakeholders in the biotechnology industry. He manages a small team of 7 employees.
What Investors Ask About Indaptus Therapeutics, Inc. (INDP) — Healthcare
What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focused on developing anti-cancer and anti-viral immunotherapies. Their lead candidate, Decoy20, is currently in Phase I clinical trials, targeting a range of tumors including lymphoma, hepatocellular, colorectal, and pancreatic cancers, as well as hepatitis B virus and human immunodeficiency virus infections. The company aims to develop novel therapies that harness the power of the immune system to fight these diseases, addressing significant unmet medical needs in oncology and infectious diseases. Indaptus is working to advance its pipeline through clinical development and potential partnerships.
What do analysts say about INDP stock?
As of 2026-03-17, there is no available analyst coverage for Indaptus Therapeutics, Inc. (INDP). This is typical for pre-clinical stage biotechnology companies with limited trading history and market capitalization. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in early-stage biotechnology companies. Key valuation metrics are not yet applicable due to the company's pre-revenue status. Future analyst coverage will likely depend on the progress of Decoy20 through clinical trials and the company's ability to secure funding and partnerships.
What are the main risks for INDP?
Indaptus Therapeutics faces several key risks inherent to its stage and industry. Clinical trial risk is paramount, as the success of Decoy20 is uncertain and failures could significantly impact the company's value. Financial risk is also substantial, as the company relies on securing funding to support its research and development activities. Competition from larger pharmaceutical companies with greater resources poses a threat. Regulatory hurdles and the lengthy approval process for new drugs add further risk. The company's small size and limited resources also present operational challenges.
What are the key factors to evaluate for INDP?
Indaptus Therapeutics, Inc. (INDP) holds an AI score of 26/100 (low). Not financial advice.
How frequently does INDP data refresh on this page?
INDP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INDP's recent stock price performance?
Indaptus Therapeutics, Inc. (INDP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel immunotherapy approach targeting multiple cancers and viral infections. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INDP overvalued or undervalued right now?
Valuing Indaptus Therapeutics, Inc. (INDP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INDP?
Before investing in Indaptus Therapeutics, Inc. (INDP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.